Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction.
Mohamed T AbuelazmAbdelrahman AttiaMohamed AbdelnabiUzair JafarOmar AlmaadawyMohamed A ElzeftawyAbdelrahman MahmoudKhaled AlbakriBasel AbdelazeemPublished in: The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2024)
Vericiguat 10 mg was effective in reducing the composite CVS mortality and HF hospitalization, with an acceptable safety profile. This was only observed in HFrEF patients, but not in HFpEF patients. However, our data regarding other agents (riociguat and praliciguat) and HFpEF can be underpowered, warranting further RCTs to clarify vericiguat 10 mg place in HFrEF management guidelines and to investigate sGC stimulators for HFpEF in large-scale trials.
Keyphrases
- ejection fraction
- heart failure
- end stage renal disease
- aortic stenosis
- newly diagnosed
- chronic kidney disease
- prognostic factors
- clinical trial
- type diabetes
- pulmonary hypertension
- machine learning
- cardiovascular disease
- randomized controlled trial
- risk factors
- coronary artery disease
- electronic health record
- clinical practice
- artificial intelligence
- cardiovascular events
- double blind
- transcatheter aortic valve replacement